"Today Cellceutix issued an update largely to say that it has smoothed out the manufacturing process for brilacidin in anticipation of the start of a Phase 3 trial by the end of March of next year. In total, the company expects to test the drug in 1,400 patients in two Phase 3 trials, but has not said how long it expects the trials to take."
Market Data 
Markets 
AI
